The feasibility of a community-based directly administered antiretroviral therapy program

Clinical Infectious Diseases

Volumn 38, Issue SUPPL. 5, 2004, Pages

  Wohl, Amy Rock ^a   Garland, Wendy H ^a   Squires, Kathleen ^b   Witt, Mallory ^c   Larsen, Robert ^b   Kovacs, Andrea ^b   Hader, Shannon ^d   Weidle, Paul J ^d  

^a LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES   (United States)

^b Los Angeles Co Univ S CA Med C   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ETHNIC GROUP; EXPERIENCE; FEASIBILITY STUDY; FEMALE; HEALTH CARE PERSONNEL; HEALTH CENTER; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; INTERPERSONAL COMMUNICATION; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICAL STAFF; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; UNITED STATES; URBAN POPULATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HEALTH PERSONNEL; HEALTH PLANNING GUIDELINES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; POVERTY;

EID: 2942592238     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421401     Document Type: Article

References (24)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
2. Panel on Clinical Practices for the Treatment of HIV Infection, convened by the US Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. DHHS, 4 February 2002. Available at: http://www.aidsinfo.nih.gov/guidelines/adult/archive/AA_020402.html. Accessed 7 May 2004.
3. Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000; 23:386-95.
4. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002; 29:S2-10.
5. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biological outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002; 34:1115-21.
6. Tuldra A, Fumaz C, Ferrrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25:221-8.
7. Núñez M, Soriano V. Salvage therapy for HIV infection: when and how. AIDS Patient Care STDs 2000; 14:465-76.
8. Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000; 23:386-95.
9. Montaner JSG, Reiss R, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA 1998; 279:930-7.
10. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279:1977-83.
11. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologie and immunologic response. AIDS 1999; 13:1099-107.
12. Honghu L, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134:968-77.
13. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-36.
14. Mostashari F, Riley E, Selwyn PA, Altice FL. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional setting. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:341-8.
15. Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13:1763-9.
16. Fischl M, Rodriguez E, Scerpella R, et al. Impact of directly observed therapy on outcomes in HIV clinical trials [abstract 528]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retroviruses and Human Health, 2000.
17. Babudieri S, Aceti A, D'Offizi, et al. Directly observed therapy to treat HIV infection in prisoners. JAMA 2000; 284:179-80.
18. Mitty JA, Mckenzie, M, Stensel M, et al. Modified directly observed therapy for treatment of human immunodeficiency virus. JAMA 1999; 282:1334.
19. Gigliotti F, Murante BL, Weinberg GA. Short course directly observed therapy to monitor compliance with antiretroviral therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2001; 20:716-8.
20. Katz MH, Cunningham WE, Fleishman JA, et al. Effect of case management on unmet needs and utilization of medical care and medication among HIV-infected persons. Ann Intern Med 2001; 135:557-65.
21. Weiss LJW, French PTF, Waters MDW, et al. Adherence support: the importance of linkages to clinical care [abstract MoPeB3284]. In: Proceedings of the XIV International AIDS Conference (Barcelona), 2002.
22. United Way of Greater Los Angeles. State of the County Report. Los Angeles: United Way of Greater Los Angeles, 1999.
23. Frye D. New HIV infections and persons living with HIV/AIDS among behavioral risk groups in Los Angeles County. Presentation to the Los Angeles County Prevention Planning Committee, 7 January 2003. Available at: http://lapublichealth.org/hiv/hivpresentations.htm. Accessed 7 May 2004.
24. HIV Epidemiology Program, Los Angeles County Department of Health Services. Advanced HIV disease (AIDS) surveillance summary, 15 January 2003. 2003:1-26.